Manage your formulary budget
Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Certain ergot peptide alkaloids administered to the nasal mucosa|
|Abstract:||The present invention provides a nasal pharmaceutical composition comprising as active agent a compound of formula I, ##STR1## wherein R.sub.1 is hydrogen or halogen, R.sub.2 is hydrogen or alkyl of 1 to 4 carbon atoms, either (i) R.sub.3 is isopropyl, sec-butyl, or isobutyl, R.sub.4 methyl, ethyl or isopropyl and R.sub.5 hydrogen and R.sub.6 is hydrogen or methoxy or R.sub.5 and R.sub.6 are together a single bond, or (ii) R.sub.3 is benzyl, R.sub.4 is methyl, R.sub.5 is hydrogen and R.sub.6 is hydrogen or methoxy, in association with a pharmaceutically acceptable carrier or diluent, adapted for nasal or pulmonary administration.|
|Inventor(s):||Azria; Moise (Paris, FR), Cavanak; Thomas (Oberwil, CH)|
|Assignee:||First Fidelity Bank, National Association, New Jersey (Newark, NJ)|
Patent Claim Types:|
see list of patent claims
|Composition; Compound; Delivery; Formulation;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.